[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Danish Study Group\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100480339","coronary-artery-bypass-grafts-or-percutaneous-coronary-intervention-for-high-risk-patients-100480339",false,"NCT05534698","Coronary Artery Bypass Grafts or Percutaneous Coronary Intervention for High Risk Patients","Coronary Artery Bypass Grafts or Percutaneous Coronary Intervention for Revascularization in Moderate to Highs Risk Patients With Ischemic Heart Disease and Reduced Left Ventricular Ejection Fraction","Inclusion Criteria:\n\n* Age ≥ 18 years\n\n  * LVEF\\\u003C45% with or without HF medication\n  * Heart team believes that a meaningful revascularization can be achieve both by PCI and by CABG\n  * Patients with severe CAD, where guidelines suggest equipoise between PCI and CABG\n\nExclusion Criteria:\n\n* Decompensated HF requiring inotropic\u002Fadrenergic support, invasive or non-invasive ventilation or intra-aortic balloon pump\u002F ventricular assist device therapy less than 48 hours prior to randomization\n\n  * Recent (\\\u003C 1 month) ST-elevation myocardial infarction\n  * Recent (\\\u003C 1 month) type 2 myocardial infarction ▪ Valvular heart disease or any other cardiac conditions (for example, left ventricular aneurysm) indicating the need for surgical repair\u002Freplacement\n  * Prohibitive bleeding risk or clinical scenario mandating avoidance of long-term dual antiplatelet therapy\n  * Pregnancy","ALL","18 Years","100 Years",{"count":20,"type":21},1550,"ESTIMATED","INTERVENTIONAL",[24],"NA","Most patients with Left Ventricular Systolic Dysfunction (LVSD) or heart failure (HF) have coronary artery disease (CAD) while some patients also have renal disease. Life-saving revascularization is underperformed in patients with LVSD or HF due to CAD, and especially if there is concomitant renal disease. We hypothesize that PCI will be non-inferior to CABG for all-cause mortality and recurrent myocardial infarction (MI), stroke or hospitalization for HF. To compare revascularization by PCI versus by CABG, we will perform a multicentre, open-label, parallel, randomized, controlled trial in patients with severe CAD who belong to defined categories of moderate-to-high risk characteristics, where guidelines acknowledge that both PCI and CABG are relevant treatment options.",[27,28],"IHD","LV Dysfunction","NOT_YET_RECRUITING","2022-09-11",{"date":32,"type":33},"2022-09-15","ACTUAL",{"date":35,"type":21},"2022-10",{"date":37,"type":21},"2033-02",{"name":39,"class":40},"Danish Study Group","NETWORK",""]